Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug
maker marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
Attorney General Richard
Blumenthal says federal regulators approved Zyprexa for schizophrenia and bipolar disorder. But he says the company also promoted
it for dementia, attention-deficit disorder and other unapproved uses that caused some patients to develop diabetes, heart
problems and other ailments.
Indianapolis-based Lilly settled similar federal claims for $1.42 billion in January.
A spokeswoman says the company admits no wrongdoing, and it has now settled lawsuits with three of 13 states that sued. The
two other settlements are with Alaska and West Virginia.